What is the 13F Pro Quality Score for HALO?

13F Pro ranks HALOZYME THERAPEUTICS, INC. (HALO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HALO's current score at https://13fpro.ai/research/HALO (free sign-up required for the full ranking).

Where does 13F Pro source HALO data?

All HALOZYME THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. HALOZYME THERAPEUTICS, INC. files with the SEC under CIK 1159036. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HALO in?

HALOZYME THERAPEUTICS, INC. (HALO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives HALO's revenue?

Per HALOZYME THERAPEUTICS, INC.'s latest 10-Q filed with the SEC on 2026-05-11, the biggest revenue drivers are: Royalties ($240.7M, +43% YoY); Product sales, net ($130.4M, +67% YoY); Bulk rHuPH20 sales ($73.5M, +172% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/HALO.

What are HALO's largest expenses?

HALOZYME THERAPEUTICS, INC.'s latest 10-Q reports these as the largest expense items: Cost of sales ($79.2M, +64% YoY); Amortization of intangibles ($29.5M, +66% YoY); Research and development ($25.6M, +73% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is HALO research updated on 13F Pro?

HALO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HALOZYME THERAPEUTICS, INC.(HALO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1159036 HALO stock profile & AI dashboard →

13F Pro Quality Score

81.2/100

Rank #32 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

86.9/100

Profitability

94.9/100

Balance Sheet

98.0/100

Earnings Quality

84.4/100

Free Cash Flow

91.6/100

Institutional Flow

48.6/100

Revenue Scale

54.5/100

Dilution Risk

30.5/100

HALO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for HALOZYME THERAPEUTICS, INC. (HALO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HALO at 81.2/100 on a 32-signal composite quality model, placing it at rank #32 of 2,879 stocks — the top 5% of the AI-ranked universe. HALO scores in the top quartile across balance sheet strength (98.0), profitability (94.9), free cash flow (91.6). Shareholder dilution risk is elevated at 30.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), HALOZYME THERAPEUTICS, INC. reports quarterly revenue of $376.7M, net income of $150.0M, free cash flow of $176.3M. Top institutional holders of HALO by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. HALO trades on the Nasdaq exchange and files with the SEC under CIK 1159036. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HALO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HALOZYME THERAPEUTICS, INC. directly from SEC EDGAR. HALOZYME THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 8 and 87 since 2021, currently 81.2 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about HALOZYME THERAPEUTICS, INC.

Quirks, history, and lore behind HALO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Annual revenue in the hundreds of millions, driven almost entirely by royalties and licensing deals rather than selling drugs directly to patients.
3
The History
Founded in the early 2000s, the company spent years developing a single platform technology before pivoting to a royalty-based business model that made it far more profitable than a typical biotech.
4
The Secret
Its crown jewel is an enzyme technology that makes drugs absorb faster and more efficiently — essentially a biological shortcut that other drugmakers pay handsomely to borrow.
5
The Lore
Its ENHANZE drug-delivery platform is embedded in blockbuster treatments sold by Roche, Pfizer, Janssen, and others — meaning it quietly profits every time those giant drugs are administered.
6
The Giveaway
The company's name literally nods to hyaluronidase — the enzyme at the heart of its ENHANZE technology — and its ticker is the friendliest four letters in biotech: HALO.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving HALO's Business? Latest 10-Q Breakdown

AI-extracted from HALOZYME THERAPEUTICS, INC.'s 10-Q filed 2026-05-11 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Royalties surged 43% YoY to $240.7M and total revenue reached $376.7M (+43% YoY), driven by DARZALEX SC, VYVGART Hytrulo, and Phesgo sales uptake.

Biggest Revenue Drivers

Total revenue: $376.7M+43% YoY

Royalties$240.7M+43% YoY

Continued sales uptake of ENHANZE partner products predominantly DARZALEX SC by Janssen, VYVGART Hytrulo by argenx, and Phesgo by Roche.

Product sales, net$130.4M+67% YoY

Increased sales of bulk rHuPH20 driven by partner demand and XYOSTED proprietary product market growth.

Within Product sales, net

Bulk rHuPH20 sales$73.5M+172% YoY

Partner demand for bulk rHuPH20 increased substantially.

Proprietary product sales$41.9M+15% YoY

XYOSTED market growth as we continue to gain share in testosterone replacement therapy.

Revenues under collaborative agreements$5.6M-70% YoY

Decrease due to timing of milestones achieved; these revenues fluctuate based on partner clinical, regulatory and milestone achievements.

Largest Expense Items

Cost of sales$79.2M+64% YoY

Increase primarily due to higher bulk rHuPH20 sales volume.

Amortization of intangibles$29.5M+66% YoY

Increase due to acquisition of Elektrofi in November 2025.

Research and development$25.6M+73% YoY

Increase primarily due to Elektrofi and Surf Bio acquisitions in Q4 2025.

Selling, general and administrative$57.9M+37% YoY

Increase in consulting and professional services including patent litigation, acquisitions, and compensation expenses.

Margins: Operating income increased 30% YoY to $184.5M despite operating expenses rising 56%, as revenue growth of 43% outpaced cost increases. Gross margin contracted due to cost-of-sales growth from bulk rHuPH20 manufacturing, though offset by higher-margin royalty revenues.

Watch Items from the Filing

Elektrofi acquisition ($810.4M paid November 2025) includes contingent consideration risk: partner currently evaluating potential return of a target with decision expected by September 2026; material interim impairment of intangibles and goodwill possible if target returns without alternative.
Significant debt refinancing completed: $1.5B of 2031 and 2032 Convertible Notes issued November 2025, with $1.02B used to repurchase 2027 and 2028 notes; total convertible debt now $2.18B principal.
Hypercon and Surf Bio integration underway post-acquisition; Hypercon customer relationships valued at $470M (15-year amortization) and Surf Bio contingent milestone payments of up to $100M dependent on future development success.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$376.7M

Net Income

Q1 2026

$150.0M

Free Cash Flow

Q1 2026

$176.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+22.4% YoY

$1.02BFY 2024

FY21 $443.3MFY22 $660.1MFY23 $829.3MFY24 $1.02B

Net Income

+57.7% YoY

$444.1MFY 2024

FY21 $402.7MFY22 $202.1MFY23 $281.6MFY24 $444.1M

Operating Income

+63.4% YoY

$551.5MFY 2024

FY21 $275.9MFY22 $267.5MFY23 $337.6MFY24 $551.5M

EPS (Diluted)

+63.3% YoY

$3.43FY 2024

FY21 $2.74FY22 $1.44FY23 $2.10FY24 $3.43

Total Assets

+19.1% YoY

$2.06BFY 2024

FY21 $1.10BFY22 $1.84BFY23 $1.73BFY24 $2.06B

Total Debt

+0.4% YoY

$1.51BFY 2024

FY21 $966.1MFY22 $1.52BFY23 $1.50BFY24 $1.51B

Op. Cash Flow

+23.3% YoY

$479.1MFY 2024

FY21 $299.4MFY22 $240.1MFY23 $388.6MFY24 $479.1M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$1.02B +22.4%	$829.3M +25.6%	$660.1M +48.9%	$443.3M +65.7%	$267.6M +76.2%	$151.9M
Net Income	$444.1M +57.7%	$281.6M +39.3%	$202.1M -49.8%	$402.7M +212.0%	$129.1M +260.7%	$-80.3M
Operating Income	$551.5M +63.4%	$337.6M +26.2%	$267.5M -3.0%	$275.9M +91.3%	$144.3M +308.1%	$-69.3M
EPS (Diluted)	$3.43 +63.3%	$2.10 +45.8%	$1.44 -47.4%	$2.74 +201.1%	$0.91 +262.5%	$-0.56
Total Assets	$2.06B +19.1%	$1.73B -5.9%	$1.84B +66.7%	$1.10B +90.4%	$579.9M +31.7%	$440.2M
Total Debt	$1.51B +0.4%	$1.50B -1.3%	$1.52B +57.3%	$966.1M +143.2%	$397.2M +214.3%	$126.4M
Operating Cash Flow	$479.1M +23.3%	$388.6M +61.8%	$240.1M -19.8%	$299.4M +440.0%	$55.5M +212.0%	$-49.5M

Get alerted when HALO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HALOZYME THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HALO

BlackRock, Inc.
$857.3M13,265,053 sh
VANGUARD CAPITAL MANAGEMENT LLC
$340.7M5,271,218 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$339.3M5,249,206 sh
STATE STREET CORP
$319.1M4,937,854 sh
Invesco Ltd.
$259.3M4,012,494 sh
BANK OF AMERICA CORP /DE/
$188.3M2,913,109 sh
Boston Partners
$173.4M2,683,683 sh
MORGAN STANLEY
$165.6M2,562,309 sh
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$163.3M2,525,975 sh
GEODE CAPITAL MANAGEMENT, LLC
$162.0M2,505,786 sh

Fund	Value	Shares
BlackRock, Inc.	$857.3M	13,265,053
VANGUARD CAPITAL MANAGEMENT LLC	$340.7M	5,271,218
VANGUARD PORTFOLIO MANAGEMENT LLC	$339.3M	5,249,206
STATE STREET CORP	$319.1M	4,937,854
Invesco Ltd.	$259.3M	4,012,494
BANK OF AMERICA CORP /DE/	$188.3M	2,913,109
Boston Partners	$173.4M	2,683,683
MORGAN STANLEY	$165.6M	2,562,309
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$163.3M	2,525,975
GEODE CAPITAL MANAGEMENT, LLC	$162.0M	2,505,786

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HALO on your watchlist

Track score changes the day HALOZYME THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HALO a good stock to buy?

13F Pro's AI-powered analysis of HALOZYME THERAPEUTICS, INC. (HALO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HALO are available on the HALO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HALO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HALO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HALOZYME THERAPEUTICS, INC.'s investment landscape.